Molecular pathways and therapeutic targets involved in lupus nephritis (LN) (IMAGE)
Caption
SLE involves abnormal activation of both innate and adaptive immune responses, leading to systemic immune dysregulation and renal impairment. The complement system's dysfunction impedes DNA degradation, prompting activation of innate immunity and accumulation of type I IFNs and pro-inflammatory cytokines. Concurrently, impaired adaptive immunity fosters autoreactive T-cells and autoantibodies, contributing to renal damage and LN progression. Targeted therapies utilize a range of biological agents and small molecule inhibitors targeting specific immune cells and pathways involved in LN. The figure succinctly depicts the initiation and progression of SLE and LN, highlighting therapeutic targets and therapies currently under investigation.
Credit
Dr. Wei Chen from the Department of Nephrology of the First Affiliated Hospital, Sun Yat-Sen University, China
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND